We found that the combination of MerTK ASO with radiotherapy and anti-PD1 or anti-CTLA4 significantly enhances the anti-tumor immune response and improves treatment efficacy in both the primay, irradiated tumors and secondary, unirradiated tumors in an anti-PD1-resistant lung cancer model. Here, MERTK is linked to neoplasm.